胱氨酸-谷氨酸逆向转运体xCT(SLC7A11)高表达是胶质瘤诊断时癫痫发作的独立生物标志物
研究纳入215例连续新诊断胶质瘤患者,用组织微阵列免疫组化检测xCT最大表达量,并结合组织学分级与IDH1 R132H状态分析其与癫痫发作的关系。结果显示高xCT表达与诊断时癫痫发作显著相关(OR 2.2,p=0.02),但与生存无关(p=0.27)。
要点
- 高xCT表达与胶质瘤诊断时癫痫发作独立相关,OR 2.2(p=0.02)。
- 低级别胶质瘤(WHO II/III级)xCT表达低于胶质母细胞瘤(p=0.001)。
- xCT表达与生存无显著相关(p=0.27,log-rank检验)。
核心结论
- 高xCT表达是胶质瘤相关癫痫发作的独立标志物,尤其在高grade胶质瘤中,但在本队列中与更差生存无关。
研究设计与样本
- 研究为对229例连续新诊断胶质瘤患者的队列分析,排除14例后纳入215例(7.4%为II级,7.0%为III级,85.6%为IV级)。
- 用组织微阵列对每例肿瘤中央区1-3个独立样本行免疫组化,测定xCT最大表达,并以免疫组化确定IDH1 R132H突变状态。
主要发现
- 高xCT表达与起病时癫痫发作显著相关(p=0.05),但与癫痫发作的发生或难治性癫痫无关。
- 低级别胶质瘤(WHO II/III级)xCT表达低于胶质母细胞瘤(p=0.001),无IDH1 R132H突变的肿瘤xCT水平趋于更高(p=0.07)。
- 多因素分析中,高xCT表达与WHO肿瘤分级与诊断时癫痫发作显著相关(比值比2.2,p=0.02),IDH1 R132H突变则不然。
- xCT表达与生存无相关(p=0.27,log-rank检验)。
关键数值与推荐
- 高xCT表达与诊断时癫痫发作的比值比为2.2(p=0.02)。
- 低级别胶质瘤(WHO II/III级)与胶质母细胞瘤的xCT表达比较p=0.001。
- 无IDH1 R132H突变肿瘤xCT水平趋高,p=0.07。
- xCT表达与生存比较p=0.27(log-rank检验)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epileptic seizures are an important cause of morbidity in glioma patients. Substantial lines of evidence support the concept of the excitatory neurotransmitter glutamate being a crucial mediator of glioma-associated seizures. In gliomas, non-vesicular secretion of glutamate via the cystine-glutamate exchanger (SLC7A11, xCT) constitutes the main mechanism contributing to high extracellular glutamate concentrations. However, a convincing "proof-of-relevance" of this mechanism in patient material is lacking. A cohort of 229 consecutive patients with newly diagnosed glioma was analyzed with respect to presence, time course, and severity of epileptic seizures. 14 patients were excluded due to previous epileptic seizures, insufficient clinical data or insufficient tumor material. The maximal immunohistochemical expression of xCT was determined in 1-3 independent samples from central tumor areas of each tumor using tissue microarrays. In addition to histological grading of the tumors, isocitrate dehydrogenase 1 (IDH1) R132H mutational status was determined by immunohistochemistry. 215 consecutive glioma patients were included in the study (7.4% grade II, 7.0% grade III, 85.6% grade IV). High xCT expression was significantly associated with seizures at onset (p = 0.05) but not with development of seizures or with refractory seizures. Low-grade gliomas (WHO II/III) had lower xCT expression than glioblastoma (p = 0.001), and tumors without IDH1 R132H mutation tended to have higher xCT levels (p = 0.07). In a multivariate analysis, high xCT expression and WHO tumor grade but not IDH1 R132H mutation, were significantly associated with epileptic seizures at diagnosis (odds ratio 2.2, p = 0.02). Further, xCT expression did not correlate with survival (p = 0.27, log-rank test). Thus, high xCT expression is an independent marker for glioma-associated seizures at diagnosis especially in high-grade glioma, but is not associated with worse survival in our cohort.
引用
- Sørensen MF, Heimisdóttir SB, Sørensen MD, et al. High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma. J Neurooncol. 2018. PMID: 29404978. doi:10.1007/s11060-018-2785-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。